{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:46:47Z","timestamp":1747198007454,"version":"3.40.5"},"reference-count":13,"publisher":"Walter de Gruyter GmbH","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,26]]},"DOI":"10.1515\/cclm-2024-0889","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T10:13:55Z","timestamp":1723630435000},"page":"e257-e259","source":"Crossref","is-referenced-by-count":0,"title":["Reply to: \u201cIs uracil enough for effective pre-emptive DPD testing?\u201d"],"prefix":"10.1515","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-412X","authenticated-orcid":false,"given":"Fabienne","family":"Thomas","sequence":"first","affiliation":[{"name":"Oncopole Claudius Regaud , Institut Universitaire du Cancer and CRCT, University of Toulouse, Inserm , Toulouse , France"},{"name":"French Clinical Oncopharmacology Group (GPCO)-UNICANCER , Paris , France"},{"name":"Francophone Network of Pharmacogenetics (RNPGx) , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Launay","sequence":"additional","affiliation":[{"name":"French Clinical Oncopharmacology Group (GPCO)-UNICANCER , Paris , France"},{"name":"Service de m\u00e9decine intensive et r\u00e9animation m\u00e9dicale et Centre R\u00e9gional de Pharmacovigilance , CHU de Saint-Etienne , Saint-Etienne , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Raymond","sequence":"additional","affiliation":[{"name":"Francophone Network of Pharmacogenetics (RNPGx) , Paris , France"},{"name":"D\u00e9partement de g\u00e9n\u00e9tique , Laboratoire Eurofins Biomnis , Lyon , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Guitton","sequence":"additional","affiliation":[{"name":"French Clinical Oncopharmacology Group (GPCO)-UNICANCER , Paris , France"},{"name":"Laboratoire de Biochimie et Toxicologie, Centre Hospitalier Lyon-Sud , Hospices Civils de Lyon , Pierre-B\u00e9nite , France"},{"name":"Laboratoire de Toxicologie, ISPB, Facult\u00e9 de Pharmacie , Universit\u00e9 Lyon 1, Universit\u00e9 de Lyon , Lyon , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Anne","family":"Loriot","sequence":"additional","affiliation":[{"name":"Francophone Network of Pharmacogenetics (RNPGx) , Paris , France"},{"name":"Department of Clinical Chemistry, Assistance Publique H\u00f4pitaux de Paris-Centre , H\u00f4pital Europ\u00e9en Georges-Pompidou , Paris , France"},{"name":"INSERM UMR-S1138, Centre de recherches des Cordeliers , Universit\u00e9 of Paris Cit\u00e9 , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Chatelut","sequence":"additional","affiliation":[{"name":"Oncopole Claudius Regaud , Institut Universitaire du Cancer and CRCT, University of Toulouse, Inserm , Toulouse , France"},{"name":"French Clinical Oncopharmacology Group (GPCO)-UNICANCER , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Haufroid","sequence":"additional","affiliation":[{"name":"Francophone Network of Pharmacogenetics (RNPGx) , Paris , France"},{"name":"Brussels and Clinical Chemistry Department, Louvain centre for Toxicology and Applied Pharmacology (LTAP), Institut de recherche exp\u00e9rimentale et clinique , UClouvain, Cliniques Universitaires Saint-Luc , Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christine","family":"Etienne-Grimaldi","sequence":"additional","affiliation":[{"name":"French Clinical Oncopharmacology Group (GPCO)-UNICANCER , Paris , France"},{"name":"Francophone Network of Pharmacogenetics (RNPGx) , Paris , France"},{"name":"Oncopharmacology Laboratory , Centre Antoine Lacassagne , Nice , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"2024101207143248453_j_cclm-2024-0889_ref_001","doi-asserted-by":"crossref","unstructured":"Heersche, N, Matic, M, Mathijssen, RHJ, Coenen, MJH, van Schaik, RHN. Is uracil enough for effective pre-emptive DPD testing? Clin Chem Lab Med 2024;62:e255\u20136. https:\/\/doi.org\/10.1515\/cclm-2024-0742.","DOI":"10.1515\/cclm-2024-0742"},{"key":"2024101207143248453_j_cclm-2024-0889_ref_002","doi-asserted-by":"crossref","unstructured":"Launay, M, Raymond, L, Guitton, J, Loriot, M-A, Chatelut, E, Haufroid, V, et al.. Can we identify patients carrying targeted deleterious DPYD variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis. Clin Chem Lab Med 2024;62:2415\u201324. https:\/\/doi.org\/10.1515\/cclm-2024-0317.","DOI":"10.1515\/cclm-2024-0317"},{"key":"2024101207143248453_j_cclm-2024-0889_ref_003","unstructured":"CPIC dosing guideline for fluorouracil and DPYD [Internet]. [cited 2015 Jul 7]. Available from: https:\/\/www.pharmgkb.org\/guideline\/PA166122686."},{"key":"2024101207143248453_j_cclm-2024-0889_ref_004","doi-asserted-by":"crossref","unstructured":"Arriv\u00e9, C, Fonrose, X, Thomas, F, Roth, G, Jacquet, E, Brice, A, et al.. Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: what are the explanatory factors? Br J Clin Pharmacol 2023;89:2446\u201357. https:\/\/doi.org\/10.1111\/bcp.15715.","DOI":"10.1111\/bcp.15715"},{"key":"2024101207143248453_j_cclm-2024-0889_ref_005","doi-asserted-by":"crossref","unstructured":"Royer, B, Launay, M, Ciccolini, J, Derain, L, Parant, F, Thomas, F, et al.. Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping. ESMO Open 2023;8:101577. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101577.","DOI":"10.1016\/j.esmoop.2023.101577"},{"key":"2024101207143248453_j_cclm-2024-0889_ref_006","doi-asserted-by":"crossref","unstructured":"Maillard, M, Launay, M, Royer, B, Guitton, J, Gautier-Veyret, E, Broutin, S, et al.. Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency. Br J Clin Pharmacol 2023;89:762\u201372. https:\/\/doi.org\/10.1111\/bcp.15536.","DOI":"10.1111\/bcp.15536"},{"key":"2024101207143248453_j_cclm-2024-0889_ref_007","unstructured":"Haute autorit\u00e9 de Sant\u00e9 HAS IN du C. M\u00e9thodes de recherche d\u2019un d\u00e9ficit en dihydropyrimidine deshydrog\u00e9nase visant \u00e0 pr\u00e9venir certaines toxicit\u00e9s s\u00e9v\u00e8res associ\u00e9es aux traitements incluant une fluoropyrimidine (5-fluorouracile ou cap\u00e9citabine). [Internet]. Available from https:\/\/www.has-sante.fr\/jcms\/c_2891090\/fr\/methodes-de-recherche-d-un-deficit-en-dihydropyrimidine-deshydrogenase-visant-a-prevenir-certaines-toxicites-severes-associees-aux-traitements-incluant-une-fluoropyrimidine-5-fluorouracile-ou-capecitabine."},{"key":"2024101207143248453_j_cclm-2024-0889_ref_008","doi-asserted-by":"crossref","unstructured":"Thomas, F, Hennebelle, I, Delmas, C, Lochon, I, Dhelens, C, Garnier Tixidre, C, et al.. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil\/uracil ratio. Clin Pharmacol Ther 2016;99:235\u201342. https:\/\/doi.org\/10.1002\/cpt.210.","DOI":"10.1002\/cpt.210"},{"key":"2024101207143248453_j_cclm-2024-0889_ref_009","doi-asserted-by":"crossref","unstructured":"Morel, A, Boisdron-Celle, M, Fey, L, Lain\u00e9-Cessac, P, Gamelin, E. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin Biochem 2007;40:11\u20137. https:\/\/doi.org\/10.1016\/j.clinbiochem.2006.07.012.","DOI":"10.1016\/j.clinbiochem.2006.07.012"},{"key":"2024101207143248453_j_cclm-2024-0889_ref_010","doi-asserted-by":"crossref","unstructured":"Henricks, LM, Lunenburg, CATC, de Man, FM, Meulendijks, D, Frederix, GWJ, Kienhuis, E, et al.. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 2018;19:1459\u201367. https:\/\/doi.org\/10.1016\/s1470-2045(18)30686-7.","DOI":"10.1016\/S1470-2045(18)30686-7"},{"key":"2024101207143248453_j_cclm-2024-0889_ref_011","doi-asserted-by":"crossref","unstructured":"Le Teuff, G, Cozic, N, Boyer, J-C, Boige, V, Diasio, RB, Taieb, J, et al.. Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis. Br J Cancer 2024;130:808\u201318. https:\/\/doi.org\/10.1038\/s41416-023-02517-2.","DOI":"10.1038\/s41416-023-02517-2"},{"key":"2024101207143248453_j_cclm-2024-0889_ref_012","doi-asserted-by":"crossref","unstructured":"van Kuilenburg, ABP, Pleunis-van Empel, MCH, Brouwer, RB, Sijben, AEJ, Knapen, DG, Oude Munnink, TH, et al.. Lethal capecitabine toxicity in patients with complete dihydropyrimidine dehydrogenase deficiency due to ultra-rare DPYD variants. JCO Precis Oncol 2024;8:e2300599. https:\/\/doi.org\/10.1200\/PO.23.00599.","DOI":"10.1200\/PO.23.00599"},{"key":"2024101207143248453_j_cclm-2024-0889_ref_013","doi-asserted-by":"crossref","unstructured":"Zaanan, A, Pallet, N, Narjoz, C, Loriot, M-A, Hafliger, \u00c9. A fatal case of 5-FU toxicity despite dose adjustment in a patient with a partial DPD deficiency receiving the FLOT regimen. Eur J Cancer 2024;205:114102. https:\/\/doi.org\/10.1016\/j.ejca.2024.114102.","DOI":"10.1016\/j.ejca.2024.114102"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2024-0889\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2024-0889\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T07:24:57Z","timestamp":1728717897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2024-0889\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":13,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6,12]]},"published-print":{"date-parts":[[2024,11,26]]}},"alternative-id":["10.1515\/cclm-2024-0889"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2024-0889","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"type":"print","value":"1434-6621"},{"type":"electronic","value":"1437-4331"}],"subject":[],"published":{"date-parts":[[2024,8,15]]}}}